AstraZeneca will pay Insitro $40 million upfront and up to $1.46 billion in milestones for exclusive worldwide rights to AI-identified drug programs. The partnership targets fatty liver disease and cardiomyopathies. Insitro uses its AI platform to find disease root causes. AstraZeneca handles clinical development and commercialization.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
